Researchers from the CIBBIM- Nanomedicine Drug Delivery and Targeting group, led by Dr. Simó Schwartz at Vall d’Hebron Institute of Research (VHIR), have participated in the development of novel F3-targeted pH-sensitive liposomes, to enable the intracellular delivery of siRNA toward both cancer and endothelial cells. The study, entitled “Efficient intracellular delivery of siRNA with a safe multitargeted lípid-based nanoplatform”, has been published in "http://www.futuremedicine.com/doi/abs/10.2217/nnm.12.174?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed" Nanomedicine and led by Dr. Gomes-da-Silva, from the University of Coimbra (Portugal).VHIR researchers carried out the in vitro and in vivo validation of the new delivery systems, based on novel F3-targeted liposomes with adequate features for systemic administration. The new system constitutes a valuable tool for the specific and safe systemic delivery of siRNA to solid tumors, and may generate, in a future, effective new drugs for gene therapy and against neovascularization.